Vaccine最新文献

{"title":"Effective integration of COVID-19 vaccination with routine immunization: A case study from Kinshasa, DRC","authors":"Guillaume Mwamba ,&nbsp;Emily Margaret Gibson ,&nbsp;Carla Toko ,&nbsp;Christelle Tunda ,&nbsp;Yves Rolland Kouabenan ,&nbsp;Joseph Musenga ,&nbsp;Benedicte Waula ,&nbsp;Freddy Nkosi ,&nbsp;Mireille Mutuale Ciabu Nkima ,&nbsp;Jean Mupenda ,&nbsp;Emily Lawrence ,&nbsp;Mariam Zameer ,&nbsp;Patou Musumari","doi":"10.1016/j.vaccine.2024.126392","DOIUrl":"10.1016/j.vaccine.2024.126392","url":null,"abstract":"<div><h3>Background</h3><div>In response to the challenge of maintaining COVID-19 vaccination coverage amidst the pandemic, VillageReach, in collaboration with the Ministry of Public Health Prevention and Hygiene in Kinshasa, DRC, integrated COVID-19 vaccination with routine immunization services at two primary healthcare facilities. This initiative, launched in July 2022, represented the first of its kind in the DRC, aiming to assess the effectiveness and scalability of a multimodal vaccination approach.</div></div><div><h3>Methods</h3><div>Through a rapid appraisal involving key informant interviews and analysis of pre- and post-integration service delivery data, this case study explores the operational dynamics and outcomes of integrating COVID-19 and routine immunizations.</div></div><div><h3>Results</h3><div>Results demonstrated that the integrated approach not only maintained COVID-19 vaccine coverage but also significantly enhanced routine immunization uptake, particularly among under-immunized and zero-dose children. Overall, the vaccination sites, outreach, and integrated health facilities administered 229,983 (33 %) of COVID-19 vaccines in Kinshasa, of which 53 % were referred by community health workers. Additionally, 998 under-immunized children received routine immunizations, of whom 126 were zero-dose children. Key success factors included sustained community health worker engagement, neighborhood-specific strategies, accessible vaccination points, and robust data management. The findings suggest that such integrative strategies can effectively bolster immunization coverage in urban poor communities, offering valuable insights for similar initiatives in the DRC and beyond.</div></div><div><h3>Conclusion</h3><div>This study advocates for sustained investment in innovative immunization models to strengthen primary healthcare systems post-pandemic.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"42 ","pages":"Article 126392"},"PeriodicalIF":4.5,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142378761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the characteristics of mumps outbreaks in Fujian Province, China","authors":"Ruihong Wu ,&nbsp;Zhifei Chen ,&nbsp;Xiuhui Yang ,&nbsp;Yahong Chen ,&nbsp;Danhong Chen ,&nbsp;Hairong Zhang ,&nbsp;Yong Zhou ,&nbsp;Weiyi Pan ,&nbsp;Dong Li","doi":"10.1016/j.vaccine.2024.126415","DOIUrl":"10.1016/j.vaccine.2024.126415","url":null,"abstract":"<div><h3>Objectives</h3><div>Identifying the specifics and potential causes of mumps outbreaks in the Fujian Province during the period of 2017 to 2022.</div></div><div><h3>Methods</h3><div>Mumps cases reported by the National Notifiable Communicable Disease Report System (NNCDRS) in China during the observation period of the 5 years were investigated annually and by age to detect homogeneity of the spread of the disease over time. If specific age-peaks may appear, we investigated those figures by analysing group characteristics in mumps cases presented as outbreaks. Those characteristics include demography (age and sex), clinical symptoms, place and time identification, and vaccination status. Regarding the latter, it was hypothesized that cases manifesting an outbreaks and appearing in young adults should have a low vaccination coverage, and a long-lasting period since they received their vaccine.</div></div><div><h3>Results</h3><div>The total number of mumps cases reported during the observation period was 15,294, leading to incidence rates ranging from 3.2/100,000 to 8.0/100,000 per year. In the older age-group the disease spread by year and age (9 to 15y old) manifested 20 outbreaks accounting for 710 cases, all happening during 2017 to 2019. Thereafter those outbreaks disappeared in that age-group. The group characteristics specified that all the outbreaks happened in school settings, with a median age of 13y (range 6 to 19y). Parotid gland enlargement was observed in 82.7 %. The median duration of the outbreaks was 28 days, varying from 14 to 74 days. Only 27.6 % of the cases received at least one dose of the MuCV vaccine, and among these vaccinated individuals, 94.9 % developed mumps more than 5 years after vaccination. The dramatic reduction in outbreaks after 2019 could be explained by the public health measures taken during the COVID period and/or the new vaccination policy implemented in 2008 (free vaccination, 1 dose) and 2020 (2 doses) of young children causing therefore a lower rate of circulation of the virus.</div></div><div><h3>Conclusion</h3><div>Mumps outbreaks observed in young adults during 2017–2019 causing a disease peak, indicated a potential link to unsatisfactory vaccination coverage with prolonged interval since receiving the vaccine. As those disease peaks disappeared since 2020, close monitoring for new outbreaks in young adults is recommended that may initiate a new vaccination strategy for that age-group.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"42 26","pages":"Article 126415"},"PeriodicalIF":4.5,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142378763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refinement and optimisation of Neisseria gonorrhoeae NHBA and MetQ vaccine candidates","authors":"Taha,&nbsp;Sharareh Eskandari,&nbsp;Valentin A. Slesarenko,&nbsp;Thomas Haselhorst,&nbsp;Evgeny A. Semchenko ,&nbsp;Kate L. Seib","doi":"10.1016/j.vaccine.2024.126416","DOIUrl":"10.1016/j.vaccine.2024.126416","url":null,"abstract":"<div><div><em>Neisseria gonorrhoeae</em> has a significant impact on reproductive health with an estimated 82 million new cases of infection per year worldwide. Due to the ongoing emergence of multidrug-resistant <em>N. gonorrhoeae</em> strains<em>,</em> the high number of asymptomatic cases, and the risk of disease sequelae, the development of a gonococcal vaccine is urgently needed. We have previously described two potential gonococcal vaccine antigens, cNHBA (C-terminal fragment of the Neisseria Heparin Binding Antigen) and MetQ (methionine-binding protein). This study aimed to optimise these antigens for improved immune responses and to facilitate vaccine production, by investigating cNHBA fusions with the full-length MetQ protein or N-terminal and C-terminal MetQ fragments (Met1 and Met2, respectively) adjuvanted with aluminium hydroxide. The cNHBA and MetQ fragments and fusion antigens were all immunogenic in mice, generating a predominantly IgG1 response. Antibodies mediated bacterial killing <em>via</em> both serum bactericidal activity (SBA) and opsonophagocytic activity (OPA), and reduced adherence to cervical and urethral epithelial cells. Among the antigen fusions tested, MetQ-cNHBA and cNHBA-Met2 generated the highest SBA, OPA and adherence blocking titres and are proposed as promising optimised antigens for <em>N. gonorrhoeae</em> vaccine development.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"42 26","pages":"Article 126416"},"PeriodicalIF":4.5,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142378764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety signal detected: Anaphylaxis after attenuated dengue vaccine (TAK-003) – Brazil, march 1, 2023-march 11, 2024","authors":"Jadher Percio,&nbsp;Carla Dinamerica Kobayashi,&nbsp;Roberta Mendes Abreu Silva,&nbsp;Ana Karolina Barreto Berselli Marinho,&nbsp;Leon Capovilla,&nbsp;Paulo Henrique Santos Andrade,&nbsp;Martha Elizabeth Brasil da Nóbrega,&nbsp;Cibelle Mendes Cabral,&nbsp;Monica Brauner de Moraes,&nbsp;Guilherme Loureiro Werneck,&nbsp;Eder Gatti Fernandes","doi":"10.1016/j.vaccine.2024.126407","DOIUrl":"10.1016/j.vaccine.2024.126407","url":null,"abstract":"<div><div>The aim was to describe cases of anaphylaxis following the Attenuated Dengue Vaccine (TAK-003) in Brazil, from March 1, 2023, to March 11, 2024. A descriptive study of anaphylaxis cases following TAK-003 was conducted, as reported in the National System of Surveillance of Adverse Events Following Immunization (AEFI). Percentages and notification rates of AEFI per million doses administered (DA) were calculated. In total, 380,358 doses of TAK-003 were administered, and 626 AEFI were reported. Of these, 85 were cases of immediate hypersensitivity, with 24 (63.1 cases per million) being anaphylaxis, including three anaphylactic shock. For 10 (41.7 %) cases, reactions began within 15 min after vaccination. No deaths related to anaphylaxis were reported. In light of the safety signal identification (increased frequency of anaphylaxis post-dengue vaccination), the Ministry of Health of Brazil published recommendations for intensifying actions for safe vaccination, including healthcare professional training and post-vaccination observation.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"42 26","pages":"Article 126407"},"PeriodicalIF":4.5,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142378765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using regression tree analysis to examine demographic and geographic characteristics of COVID-19 vaccination trends over time, United States, May 2021–April 2022, National Immunization Survey Adult COVID Module","authors":"Morgan Earp ,&nbsp;Lu Meng ,&nbsp;Carla L. Black ,&nbsp;Rosalind J. Carter ,&nbsp;Peng-Jun Lu ,&nbsp;James A. Singleton ,&nbsp;Terence Chorba","doi":"10.1016/j.vaccine.2024.126372","DOIUrl":"10.1016/j.vaccine.2024.126372","url":null,"abstract":"<div><div>Using data from the nationally representative National Immunization Survey (NIS), we applied conditional linear regression tree methodology to examine relationships between demographic and geographic factors and propensity of receiving various doses of COVID-19 vaccine over time; these analyses identified temporal changes in these relationships that heretofore had not been identified using conventional logistical regression methodologies.</div><div>Three regression tree models were built using an R package, Recursive Partitioning for Modeling Survey (rpms), to examine propensities over time of receiving a (1) first dose of a two-dose COVID-19 mRNA primary vaccination series or single dose of the Janssen vaccine (vaccine initiation), (2) primary series completion, and (3) monovalent booster dose, using a conditional linear effect model. Persons ≥50 years were more likely to complete a primary series and receive a first booster dose; persons reporting having received non-COVID-19 vaccines recently were more likely to initiate vaccination, complete the primary series, and get a first booster dose; persons reporting having work or school requirements were more likely to complete the primary series. Persons not reporting having received non-COVID-19 vaccines in 2 years but reporting having work or school vaccination requirements were more likely to initiate vaccination than those without work/school requirements. Among persons not reporting having received non-COVID-19 vaccines in 2 years and not reporting having work or school vaccination requirements, those aged ≥50 years were more likely to initiate vaccination than were younger adults. Propensity of receiving various doses was correlated with age, having recently received non-COVID 19 vaccines, and having vaccination requirements at work or school.</div><div>Regression tree methodology enabled modeling of different COVID-19 vaccination dose propensities as a linear effect of time, revealed changes in relationships over time between demographic factors and propensity of receipt of different doses, and identified populations that may benefit from vaccination outreach efforts.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"42 26","pages":"Article 126372"},"PeriodicalIF":4.5,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142378768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serotype 15C Streptococcus pneumoniae resistant to classical complement deposition and agglutination by polyclonal rabbit anti-capsular 15B sera","authors":"E.J. Kochis ,&nbsp;Y.B. Shaik-Dasthagirisaheb ,&nbsp;N. Munarriz ,&nbsp;I. Kretzmann ,&nbsp;M. Nahm ,&nbsp;S.I. Pelton ,&nbsp;R. Lapidot","doi":"10.1016/j.vaccine.2024.126419","DOIUrl":"10.1016/j.vaccine.2024.126419","url":null,"abstract":"<div><h3>Background</h3><div><em>S. pneumoniae</em> (SP) serotypes 15B and 15C are frequent causative agents of invasive pneumococcal disease (IPD), otitis media, and nasopharyngeal colonization in the post PCV13 era. The principal difference between serotypes 15B and 15C is the presence of an <em>O</em>-acetyl group on the pentasaccharide repeating unit of 15B polysaccharide. It remains unclear if antibodies against SP15B polysaccharide demonstrate functional cross reaction with SP15C strains. We compared functional activity of polyclonal rabbit anti-capsular 15B sera against SP15B and SP15C isolates.</div></div><div><h3>Methods</h3><div>Using flow cytometry we measured complement factors C3c and C4d deposition on SP15B and 15C in the presence of polyclonal rabbit anti capsular 15B sera. We measured the binding of C3c, common to all complement pathways, and C4d, specific to classical pathway, on SP serotypes 15B and 15C when co-incubated with polyclonal rabbit anti capsular 15B sera and antibody depleted complement. Both the proportion of bacteria with complement deposition and the fluorescence intensity were measured. We also measured agglutination as the increase in forward and side scatter.</div></div><div><h3>Results</h3><div>Polyclonal rabbit anti-capsular 15B sera activated classical pathway resulting in deposition of C4d and C3c at high intensity on all SP15B cells but only achieved limited deposition and intensity of C4 with SP15C. Similarly, polyclonal rabbit anti-capsular 15B sera induced agglutination of SP15B strains in a dose dependent manner and limited agglutination of SP15C.</div></div><div><h3>Conclusions</h3><div>Anti-capsular 15B sera induce limited C4d and C3c deposition, and minimal agglutination with SP15C strains, reflecting lower classical pathway activation in contrast to high C4d and C3c deposition and agglutination of SP15B. These observations support limited functional cross reactivity of anti-15B to SP15C strains and are consistent with the reduction in opsonophagocytic killing of SP15C reported following immunization with vaccines containing 15B polysaccharide.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"42 26","pages":"Article 126419"},"PeriodicalIF":4.5,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142378766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of the Arabic translation of the vaccination attitudes examination (VAX) scale","authors":"Kamal Dhafer Hussein Alansari ,&nbsp;Caroline Buhl ,&nbsp;Abrar K. Thabit ,&nbsp;Aisha F. Badr ,&nbsp;Lama Jaad ,&nbsp;Ramune Jacobsen","doi":"10.1016/j.vaccine.2024.126411","DOIUrl":"10.1016/j.vaccine.2024.126411","url":null,"abstract":"<div><h3>Background and aim</h3><div>The availability of concise and valid instruments for measuring vaccination attitudes across different countries or populations is limited. The 12-item four-subscale Vaccination Attitudes Examination (VAX) scale designed to assess vaccination hesitancy has been validated in more than 15 languages.</div><div>This study aimed to validate the Arabic translation of VAX.</div></div><div><h3>Methods</h3><div>VAX was translated from Danish to Arabic following the Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcome Measures. The translated VAX was distributed to the citizens of Saudi Arabia in March 2023 through an online survey system and the authors' networks. Internal consistency reliability was assessed with Cronbach's α. Factorial structure was examined using confirmatory factor analysis (CFA). Known-group validity was assessed based on COVID-19 vaccination status.</div></div><div><h3>Results</h3><div>Responses from 164 participants who fully answered the questionnaire were analyzed. The mean age was 40 years, 77 % were females, and 90 % were fully vaccinated against COVID-19, with one-third receiving booster doses. CFA confirmed a well-fit four-factor structure. All items loaded well with their factors: standardized regression weight values ranged from 0.69 to 0.96. Correlations between the four factors ranged from 0.47 to 0.79. Cronbach α ranged from 0.874 to 0.930. As expected, the mean scores of all subscales were higher in those unvaccinated compared to those who were fully vaccinated as well as those fully vaccinated with a booster dose (<em>p</em> &lt; 0.05).</div></div><div><h3>Conclusion</h3><div>The Arabic translation of the VAX exhibited a well-defined factorial structure with good internal consistency reliability and known-group validity. It is a valuable tool for measuring vaccination hesitancy in Arabic-speaking countries or populations, enabling the comparison of vaccine hesitancy across different countries and cultures.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"42 26","pages":"Article 126411"},"PeriodicalIF":4.5,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142378769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors that shape COVID-19 pediatric vaccine decision-making in rural agricultural communities: A qualitative study","authors":"Kelley M. Pascoe ,&nbsp;Sonia Bishop ,&nbsp;Xuehan Ci ,&nbsp;Magaly Ramirez ,&nbsp;Georgina Perez ,&nbsp;Genoveva Ibarra ,&nbsp;Lorenzo Garza ,&nbsp;Sandra Linde ,&nbsp;Miriana C. Duran ,&nbsp;Hwa Young Chae ,&nbsp;Thomas Quigley ,&nbsp;Laurie Hassell ,&nbsp;Michelle M. Garrison ,&nbsp;Paul K. Drain ,&nbsp;Parth D. Shah ,&nbsp;Linda K. Ko","doi":"10.1016/j.vaccine.2024.126389","DOIUrl":"10.1016/j.vaccine.2024.126389","url":null,"abstract":"<div><div>While COVID-19 immunizations can improve outcomes from SARS-CoV-2, vaccine rates in the United States have been lowest among children under age 11 and among rural agricultural communities. This study examined factors influencing pediatric COVID-19 vaccine uptake among rural agricultural and predominantly Hispanic communities in Washington State. We conducted in-depth interviews with school district employees and students and held English and Spanish focus group discussions with parents, all of which were audio-recorded and transcribed. We used inductive coding with constant comparison approach to capture emergent themes. We identified five factors that influenced pediatric COVID-19 vaccine uptake in a rural community, including: 1) concerns and misinformation surrounding the new vaccine; 2) witnessing others' vaccine and pandemic experiences; 3) participation in social activities; 4) politicization of and political climate surrounding the vaccine; and 5) health education surrounding the vaccines. To increase pediatric COVID-19 vaccine uptake in rural communities, school districts, students, and parents should receive accurate information and reassurance to dispel health concerns and misinformation, without politicization of the vaccine and fears surrounding vaccine regulations. Social networks can be leveraged to encourage vaccine uptake by sharing positive vaccination vignettes.</div><div>Clinical Trial Registration: <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> Identifier: <span><span>NCT04859699</span><svg><path></path></svg></span> <span><span>https://clinicaltrials.gov/ct2/show/NCT04859699</span><svg><path></path></svg></span></div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"42 26","pages":"Article 126389"},"PeriodicalIF":4.5,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142378762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SpiN-Tec: A T cell-based recombinant vaccine that is safe, immunogenic, and shows high efficacy in experimental models challenged with SARS-CoV-2 variants of concern","authors":"Natália S. Hojo-Souza ,&nbsp;Júlia T. de Castro ,&nbsp;Graziella G. Rivelli ,&nbsp;Patrick O. Azevedo ,&nbsp;Emiliano R. Oliveira ,&nbsp;Lídia P. Faustino ,&nbsp;Natália Salazar ,&nbsp;Flávia F. Bagno ,&nbsp;Alex F. Carvalho ,&nbsp;Bruna Rattis ,&nbsp;Karine L. Lourenço ,&nbsp;Isabela P. Gomes ,&nbsp;Bruna R.D. Assis ,&nbsp;Mariela Piccin ,&nbsp;Flávio G. Fonseca ,&nbsp;Edison Durigon ,&nbsp;João S. Silva ,&nbsp;Renan P. de Souza ,&nbsp;Gisele A.C. Goulart ,&nbsp;Helton Santiago ,&nbsp;Ricardo T. Gazzinelli","doi":"10.1016/j.vaccine.2024.126394","DOIUrl":"10.1016/j.vaccine.2024.126394","url":null,"abstract":"<div><div>The emergence of new SARS-CoV-2 variants of concern associated with waning immunity induced by natural infection or vaccines currently in use suggests that the COVID-19 pandemic will become endemic. Investing in new booster vaccines using different platforms is a promising way to enhance protection and keep the disease under control. Here, we evaluated the immunogenicity, efficacy, and safety of the SpiN-Tec vaccine, based on a chimeric recombinant protein (SpiN) adjuvanted with CTVad1 (MF59-based adjuvant), aiming at boosting immunity against variants of concern of SARS-CoV-2. Immunization of K18-hACE-2 transgenic mice and hamsters induced high antibody titers and cellular immune response to the SpiN protein as well as to its components, RBD and N proteins. Importantly in a heterologous prime/boost protocol with a COVID-19 vaccine approved for emergency use (ChAdOx1), SpiN-Tec enhanced the level of circulation neutralizing antibodies (nAb). In addition to protection against the Wuhan isolate, protection against the Delta and Omicron variants was also observed as shown by reduced viral load and lung pathology. Toxicity and safety tests performed in rats demonstrated that the SpiN-Tec vaccine was safe and, based on these results, the SpiN-Tec phase I/II clinical trial was approved.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"42 26","pages":"Article 126394"},"PeriodicalIF":4.5,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142378767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IPVS STATEMENT on HPV vaccination: No longer supply constraints: Towards achieving WHO vaccine targets","authors":"Suzanne M. Garland ,&nbsp;Neerja Bhatla ,&nbsp;Yin Ling Woo","doi":"10.1016/j.vaccine.2024.126400","DOIUrl":"10.1016/j.vaccine.2024.126400","url":null,"abstract":"<div><div>The global supply of human papillomavirus (HPV) prophylactic vaccines has been constrained since 2020.Vaccine manufacturers have increased capacity and new HPV vaccines are now available. Vaccine supply is now able to meet the full HPV vaccine demand which has been achieved earlier than predicted.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"42 26","pages":"Article 126400"},"PeriodicalIF":4.5,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142376502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}